Description

Ascendis Pharma: Initiation Of Coverage – A EUR 247 Million Quarter: Can TransCon Become A Rare Disease Powerhouse?

Ascendis Pharma reported its first quarter 2026 financial results underscoring progress in its rare endocrine and growth disorder franchises, as well as pipeline developments. The company now has three FDA-approved TransCon products—YORVIPATH, YUVIWEL, and SKYTROFA—across four rare endocrine indications, reflecting a diversified portfolio within a single therapeutic area. The recent FDA approval of YUVIWEL, a once-weekly treatment for achondroplasia, marks the third TransCon product approved, with commercial availability starting in early April 2026. YORVIPATH generated EUR 197 million in global revenue for the quarter, though results were affected by two one-time factors: a temporary increase in U.S. patients receiving free drug due to reimbursement disruptions and a Europe Direct write-down related to expanded market access. Management indicated that the temporary shift in patient counts would normalize in subsequent quarters, maintaining a steady enrollment of approximately 1,000 new U.S. patients per quarter, aligning with prior guidance. Outside the U.S.